<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="other"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Gas Res</journal-id><journal-id journal-id-type="publisher-id">MGR</journal-id><journal-id journal-id-type="publisher-id">Med Gas Res</journal-id><journal-title-group><journal-title>Medical Gas Research</journal-title></journal-title-group><issn pub-type="epub">2045-9912</issn><publisher><publisher-name>Wolters Kluwer - Medknow</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC466984</article-id><article-id pub-id-type="publisher-id">MGR-14-133</article-id><article-id pub-id-type="doi">10.4103/2045-9912.385948</article-id><article-categories><subj-group subj-group-type="heading"><subject>Perspective</subject></subj-group></article-categories><title-group><article-title>Use of vedolizumab combined with hyperbaric oxygen therapy to treat enteric fistula in Crohn&#x02019;s disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bafutto</surname><given-names>Mauro</given-names></name><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5585-3957</contrib-id><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Oliveira</surname><given-names>Enio Chaves</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3502-7532</contrib-id><xref rid="aff2" ref-type="aff"/><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Bafutto</surname><given-names>Alexandre Augusto Ferreira</given-names></name><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6100-1814</contrib-id><xref rid="aff3" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Filho</surname><given-names>Carlos Alberto Ximenes</given-names></name><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1840-9018</contrib-id><xref rid="aff4" ref-type="aff"/></contrib></contrib-group><aff id="aff1">Department of Internal Medicine, School of Medicine, Universidade Federal de Goi&#x000e1;s, Goi&#x000e2;nia, Brazil</aff><aff id="aff2">Department of Surgery, School of Medicine, Universidade Federal de Goi&#x000e1;s, Goi&#x000e2;nia, Brazil</aff><aff id="aff3">Instituto Goiano de Gastroenterologia e Endoscopia Digestiva, Goi&#x000e2;nia, Brazil</aff><aff id="aff4">Department of Radiology, Hospital Ortop&#x000e9;dico de Goi&#x000e2;nia, Goi&#x000e2;nia, Brazil</aff><author-notes><corresp id="cor1"><label>*</label><italic toggle="yes"><bold>Correspondence to:</bold> Enio Chaves Oliveira, <email xlink:href="eco1.br@gmail.com">eco1.br@gmail.com</email></italic>.</corresp></author-notes><pub-date pub-type="collection"><season>Jul-Sep</season><year>2024</year></pub-date><pub-date pub-type="epub"><day>17</day><month>9</month><year>2023</year></pub-date><volume>14</volume><issue>3</issue><fpage>133</fpage><lpage>135</lpage><history><date date-type="received"><day>03</day><month>11</month><year>2021</year></date><date date-type="rev-recd"><day>21</day><month>12</month><year>2022</year></date><date date-type="accepted"><day>08</day><month>3</month><year>2023</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2024 Medical Gas Research</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions></article-meta></front><body><p>Inflammatory bowel disease (IBD) has shown a global increase, especially in developing countries.<xref rid="R1" ref-type="bibr">1</xref><xref rid="R2" ref-type="bibr">2</xref> While the USA has the highest prevalence in the world (252 to 439 cases per 100,000 people), and the UK has the highest prevalence in Europe (373 per 100,000 people).<xref rid="R3" ref-type="bibr">3</xref> IBD includes two subtypes: ulcerative colitis that is a mucosal inflammation and Crohn&#x02019;s disease (CD) that is a transmural inflammation disorder. CD may affect any part of the digestive tract but more commonly occurs in the terminal ileum. IBD etiology remains unclear but a complex immune-mediated inflammatory process in the digestive tract has been identified. An interaction of genetic factors, environmental factors, immune response and gut microbe seem to trigger the disease.<xref rid="R4" ref-type="bibr">4</xref> There is no cure to CD at the present. The main target in CD treatment is to reduce and control the inflammatory response.</p><p>Therapy for CD is determined depending on the organ involved, severity, comorbidities, outcomes and prognosis. Therapeutic options for CD include 5-aminosalicylates, antibiotics, steroids, immunosuppressants, and biologics. Biologic therapy is the use of monoclonal antibodies against specific molecular targets to stop the inflammation process in CD. The first biologics were anti-tumor necrosis factors (infliximab, adalimumab, and certolizumab pegol). New agents with different mechanisms of action have emerged: agents that block leukocyte migration, such as natalizumab, vedolizumab (VDZ); and anti-interleukin (IL)-12 and -23 agents, such as ustequinumab.</p><p>Advanced therapy for CD with biologics requires an initial high-dose induction phase followed by a maintenance dose of the chosen drug. The goal is to obtain clinical responses, including symptomatic remission and mucosal healing. In addition, as a long-lasting therapy, biologics are intended to decrease the incidence of stenosis and fistula, thereby reducing the need for surgical treatment.<xref rid="R5" ref-type="bibr">5</xref><xref rid="R6" ref-type="bibr">6</xref></p><p>Tissue hypoxia is a well-known causative factor for inflammation. Hyperbaric oxygen therapy (HBOT) has shown benefits in patients with perineal disease and entero-cutaneous fistula<xref rid="R7" ref-type="bibr">7</xref><xref rid="R8" ref-type="bibr">8</xref> and was first used as adjuvant therapy for CD in 1989.<xref rid="R9" ref-type="bibr">9</xref> The main mechanism of VDZ is its anti-integrin action, preventing the entry of leukocytes into the intestinal wall. We hypothesize that HBOT with its potent anti-inflammatory effects, combined with the VDZ that prevents the continuation of this inflammatory process in the tissue, could lead to a permanent interruption of the inflammatory stimulus, resulting in healing and tissue regeneration. We reported a complicated case of entero-enteric fistula and small bowel stenosis treated with VDZ and HBOT.</p><p>The patient was a 32-year-old white male with symptoms of severe abdominal pain, diarrhea and weight loss. He reported a history of CD for 2 years and previous use of infliximab 5 mg/kg combined with azathioprine 2.5 mg/kg without improvement.</p><p>Abdominal computed tomography scan showed entero-enteric fistula thickening and parietal stratification of the distal jejunum and terminal ileum walls (<bold><xref rid="F1" ref-type="fig">Figure 1</xref></bold>). Gastroscopy revealed severe erosive duodenitis. Fecal calprotectin level was 285 &#x003bc;g/g and C-reactive protein level was 47.6 mg/L. He was treated with vedolizumab (Hospira Inc., McPherson, KS, USA) 300 mg at 0, 2 and 6 weeks and underwent 40 sessions of HBOT with 100% oxygen concentration, pressure of 2 ATA (atmosphere absolute; 1 ATA = 760 mmHg), 2 hours/day, 7 days/week, for 40 days. After 6 weeks, the patient was asymptomatic with a normal abdominal computed tomography scan, fecal calprotectin = 4 &#x003bc;g/g and C-reactive protein &#x0003c; 6 mg/L. The patient continued to be treated with vedolizumab (300 mg, intravenous injection) every 8 weeks. After 12 months of follow-up, the patient had no abdominal discomfort, a normal abdominal computed tomography scan (<bold><xref rid="F2" ref-type="fig">Figure 2</xref></bold>) and normal levels of fecal calprotectin and C-reactive protein.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Computed tomography before treatment with vedolizumab and hyperbaric oxygen therapy in a patient with Crohn&#x02019;s disease.</p><p>Note: The circles on the computed tomography scan images indicate entero-enteric fistula and small bowel stenosis. L: Left; R: right.</p></caption><graphic xlink:href="MGR-14-133-g001" position="float"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Computed tomography 4 months after treatment with vedolizumab and hyperbaric oxygen therapy in the patient with Crohn&#x02019;s disease.</p><p>Note: The entero-enteric fistula and small bowel stenosis could not be identified on the computed tomography image. L: Left; R: right.</p></caption><graphic xlink:href="MGR-14-133-g002" position="float"/></fig><p>In this case of fistulizing and fibro-stenosing CD, the combination of VDZ with HBOT was used. We believe that the mechanism of action of HBOT could be complementary and additive to VDZ.</p><p>In recent years, HBOT has been introduced to treat complex diseases, such as tissue ischemia, neurological disorders, complications related to diabetes mellitus, neoplasms, carbon monoxide poisoning and actinic lesions.<xref rid="R10" ref-type="bibr">10</xref> Some HBOT indications remain controversial, although its adjuvant use combined with conventional medical treatment is associated with other clinical benefits. On the other hand, there are concerns related to a negative side effect of pressurized O<sub>2</sub>, such as oxidative stress injuries, DNA damage, cellular metabolism, activation of the coagulation cascade, endothelial dysfunction, neurotoxicity and pulmonary toxicity.<xref rid="R11" ref-type="bibr">11</xref></p><p>The use of HBOT involves breathing 100% oxygen under pressure, leading to an increase in plasma and tissue oxygen levels. As a result, there is relief from hypoxia and increased oxygen content in the blood reaching the inflamed intestine or chronic non-healing fistulas. It has also been reported that HBOT alters the signaling pathways involved in tissue response to hypoxia and wound repair, especially the hypoxia-inducible factor and hemeoxygenase pathways. HBOT has important anti-inflammatory effects by inhibiting the production of proinflammatory cytokines and chemokines (IL-1, IL-6, tumor necrosis factor-&#x003b1;).<xref rid="R12" ref-type="bibr">12</xref><xref rid="R13" ref-type="bibr">13</xref><xref rid="R14" ref-type="bibr">14</xref><xref rid="R15" ref-type="bibr">15</xref><xref rid="R16" ref-type="bibr">16</xref><xref rid="R17" ref-type="bibr">17</xref> It has also been observed to improve wound healing through the increase of growth factors and the migration of bone marrow-derived progenitor stem cells. Furthermore, reactive oxygen and nitrogen species generated by brief exposures to hyperbaric oxygen may act by stimulating nitric oxide synthase and vascular endothelial growth factor.<xref rid="R18" ref-type="bibr">18</xref><xref rid="R19" ref-type="bibr">19</xref><xref rid="R20" ref-type="bibr">20</xref> In addition to reducing tissue hypoxia, other factors seem to be involved in the possible beneficial effects of HBOT on IBD activity, such as improved wound healing and changes in inflammatory and immunological mediators.<xref rid="R21" ref-type="bibr">21</xref></p><p>In 2021, Wu et al.<xref rid="R22" ref-type="bibr">22</xref> reviewed clinical and experimental data on how HBOT could benefit patients with IBD by: (1) increasing colonic tissue oxygen levels; (2) blocking the release of proinflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor-&#x003b1; leading to inhibition of the inflammatory response; (3) stimulating colonic stem cell differentiation and recruitment of cells involved in the healing process; and (4) increasing the antioxidant process and reducing neutrophil migration into colonic tissue. All these known HBOT properties reinforce the possibility of its use in CD patients with small and large bowel fistula and stenosis.</p><p>Patients with CD, especially those with perineal involvement and those with moderate to severe ulcerative colitis, derive the greatest benefit from HBOT therapy, but for luminal CD without perianal disease the data in the literature are scarce and inconclusive.<xref rid="R21" ref-type="bibr">21</xref><xref rid="R23" ref-type="bibr">23</xref> The outcome of our case suggests that HBOT may be used in combination with biologic agents in a combo therapy for those patients with enteric fistulas.</p><p>VDZ is a monoclonal antibody used in the treatment of moderate and severe forms of ulcerative colitis and CD. VDZ acts as an integrin antagonist, binding to the &#x003b1;4&#x003b2;7 integrin that is expressed on T lymphocytes with gastrointestinal orientation. Binding of &#x003b1;4&#x003b2;7 integrin to mucosal addressing cell adhesion molecule-1, which is expressed on the surface of mucosal endothelial cells, is a major component of the selective homing mechanism of the intestine to lymphocytes.<xref rid="R24" ref-type="bibr">24</xref> Therefore, the main mechanism of VDZ is its anti-integrin effect, which prevents leukocytes from entering the intestinal wall, thus preventing the perpetuation and continuity of the inflammatory process.</p><p>The efficacy and safety of VDZ in the treatment of patients with CD and ulcerative colitis have been demonstrated.<xref rid="R25" ref-type="bibr">25</xref> Longterm follow-up shows persistent high response rates and clinical remission.<xref rid="R26" ref-type="bibr">26</xref> In addition, a differentiating factor in the use of VDZ compared to other biologics and monoclonal antibodies is its excellent safety profile, as VDZ is intestine-selective and theoretically associated with less systemic immunosuppression and therefore fewer adverse effects.<xref rid="R25" ref-type="bibr">25</xref><xref rid="R26" ref-type="bibr">26</xref></p><p>The patient&#x02019;s quality of life improved 1 year after HBOT. He had no longer abdominal discomfort, such as abdominal distension, abdominal pain, and diarrhea. He gained body mass and exercised twice a week.</p><p>In conclusion, the rationale of the combination of HBOT and VDZ would be the combination of all these mechanisms at the same time. Further studies are warranted in CD patients with entero-enteric fistula under the risk of multiple small bowel resections.</p><p><italic toggle="yes">This study was approved by the Ethics Committee of Hospital Estadual Geral de Goi&#x000e2;nia Dr Alberto Rassi - HGG under No. 4.335.040 on October 13, 2020. Written informed consent was obtained from the patient</italic>.</p></body><back><ref-list><title>R<sc>EFERENCES</sc></title><ref id="R1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khalili</surname><given-names>H</given-names></name></person-group><article-title>The Changing Epidemiology of inflammatory bowel disease: what goes up may come down</article-title><source>Inflamm Bowel Dis</source><year>2020</year><volume>26</volume><fpage>591</fpage><lpage>592</lpage><pub-id pub-id-type="pmid">31504537</pub-id>
</element-citation></ref><ref id="R2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ng</surname><given-names>SC</given-names></name>
<name><surname>Shi</surname><given-names>HY</given-names></name>
<name><surname>Hamidi</surname><given-names>N</given-names></name>
<etal/></person-group><article-title>Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies</article-title><source>Lancet</source><year>2017</year><volume>390</volume><fpage>2769</fpage><lpage>2778</lpage><pub-id pub-id-type="pmid">29050646</pub-id>
</element-citation></ref><ref id="R3"><label>3.</label><element-citation publication-type="journal"><collab>GBD 2017 Inflammatory Bowel Disease Collaborators</collab><article-title>The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017</article-title><source>Lancet Gastroenterol Hepatol</source><year>2020</year><volume>5</volume><fpage>17</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">31648971</pub-id>
</element-citation></ref><ref id="R4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cleynen</surname><given-names>I</given-names></name>
<name><surname>Boucher</surname><given-names>G</given-names></name>
<name><surname>Jostins</surname><given-names>L</given-names></name>
<etal/></person-group><article-title>Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study</article-title><source>Lancet</source><year>2016</year><volume>387</volume><fpage>156</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">26490195</pub-id>
</element-citation></ref><ref id="R5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lichtenstein</surname><given-names>GR</given-names></name>
<name><surname>Loftus</surname><given-names>EV</given-names></name>
<name><surname>Isaacs</surname><given-names>KL</given-names></name>
<name><surname>Regueiro</surname><given-names>MD</given-names></name>
<name><surname>Gerson</surname><given-names>LB</given-names></name>
<name><surname>Sands</surname><given-names>BE</given-names></name></person-group><article-title>ACG Clinical Guideline: management of Crohn&#x02019;s disease in adults</article-title><source>Am J Gastroenterol</source><year>2018</year><volume>113</volume><fpage>481</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">29610508</pub-id>
</element-citation></ref><ref id="R6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Torres</surname><given-names>J</given-names></name>
<name><surname>Bonovas</surname><given-names>S</given-names></name>
<name><surname>Doherty</surname><given-names>G</given-names></name>
<etal/></person-group><article-title>ECCO Guidelines on therapeutics in Crohn's disease: medical treatment</article-title><source>J Crohns Colitis</source><year>2020</year><volume>14</volume><fpage>4</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">31711158</pub-id>
</element-citation></ref><ref id="R7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feitosa</surname><given-names>MR</given-names></name>
<name><surname>Parra</surname><given-names>RS</given-names></name>
<name><surname>Machado</surname><given-names>VF</given-names></name>
<etal/></person-group><article-title>Adjunctive hyperbaric oxygen therapy in refractory Crohn&#x02019;s disease: an observational study</article-title><source>Gastroenterol Res Pract</source><year>2021</year><volume>2021</volume><fpage>6628142</fpage><pub-id pub-id-type="pmid">33995526</pub-id>
</element-citation></ref><ref id="R8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lansdorp</surname><given-names>CA</given-names></name>
<name><surname>Gecse</surname><given-names>KB</given-names></name>
<name><surname>Buskens</surname><given-names>CJ</given-names></name>
<etal/></person-group><article-title>Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease</article-title><source>Aliment Pharmacol Ther</source><year>2021</year><volume>53</volume><fpage>587</fpage><lpage>597</lpage><pub-id pub-id-type="pmid">33326623</pub-id>
</element-citation></ref><ref id="R9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brady</surname><given-names>CE</given-names><suffix>3rd</suffix></name>
<name><surname>Cooley</surname><given-names>BJ</given-names></name>
<name><surname>Davis</surname><given-names>JC</given-names></name></person-group><article-title>Healing of severe perineal and cutaneous Crohn&#x02019;s disease with hyperbaric oxygen</article-title><source>Gastroenterology</source><year>1989</year><volume>97</volume><fpage>756</fpage><lpage>760</lpage><pub-id pub-id-type="pmid">2753335</pub-id>
</element-citation></ref><ref id="R10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Wolde</surname><given-names>SD</given-names></name>
<name><surname>Hulskes</surname><given-names>RH</given-names></name>
<name><surname>Weenink</surname><given-names>RP</given-names></name>
<name><surname>Hollmann</surname><given-names>MW</given-names></name>
<name><surname>Van Hulst</surname><given-names>RA</given-names></name></person-group><article-title>The effects of hyperbaric oxygenation on oxidative stress, inflammation and angiogenesis</article-title><source>Biomolecules</source><year>2021</year><volume>11</volume><fpage>1210</fpage><pub-id pub-id-type="pmid">34439876</pub-id>
</element-citation></ref><ref id="R11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>W</given-names></name>
<name><surname>Liang</surname><given-names>X</given-names></name>
<name><surname>Nong</surname><given-names>Z</given-names></name>
<etal/></person-group><article-title>The multiple applications and possible mechanisms of the hyperbaric oxygenation therapy</article-title><source>Med Chem</source><year>2019</year><volume>15</volume><fpage>459</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">30569869</pub-id>
</element-citation></ref><ref id="R12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Speit</surname><given-names>G</given-names></name>
<name><surname>Dennog</surname><given-names>C</given-names></name>
<name><surname>Eichhorn</surname><given-names>U</given-names></name>
<name><surname>Rothfuss</surname><given-names>A</given-names></name>
<name><surname>Kaina</surname><given-names>B</given-names></name></person-group><article-title>Induction of heme oxygenase-1 and adaptive protection against the induction of DNA damage after hyperbaric oxygen treatment</article-title><source>Carcinogenesis</source><year>2000</year><volume>21</volume><fpage>1795</fpage><lpage>1799</lpage><pub-id pub-id-type="pmid">11023535</pub-id>
</element-citation></ref><ref id="R13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gu</surname><given-names>GJ</given-names></name>
<name><surname>Li</surname><given-names>YP</given-names></name>
<name><surname>Peng</surname><given-names>ZY</given-names></name>
<etal/></person-group><article-title>Mechanism of ischemic tolerance induced by hyperbaric oxygen preconditioning involves upregulation of hypoxia-inducible factor-1alpha and erythropoietin in rats</article-title><source>J Appi Physiol (1985)</source><year>2008</year><volume>104</volume><fpage>1185</fpage><lpage>1191</lpage></element-citation></ref><ref id="R14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>ZJ</given-names></name>
<name><surname>Bosco</surname><given-names>G</given-names></name>
<name><surname>Montante</surname><given-names>A</given-names></name>
<name><surname>Ou</surname><given-names>XI</given-names></name>
<name><surname>Camporesi</surname><given-names>EM</given-names></name></person-group><article-title>Hyperbaric O<sub>2</sub> reduces intestinal ischemia-reperfusion-induced TNF-alpha production and lung neutrophil sequestration</article-title><source>Eur J Appi Physiol</source><year>2001</year><volume>85</volume><fpage>96</fpage><lpage>103</lpage></element-citation></ref><ref id="R15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamashita</surname><given-names>M</given-names></name>
<name><surname>Yamashita</surname><given-names>M</given-names></name></person-group><article-title>Hyperbaric oxygen treatment attenuates cytokine induction after massive hemorrhage</article-title><source>Am J Physiol Endocrinol Metab</source><year>2000</year><volume>278</volume><fpage>E811</fpage><lpage>816</lpage><pub-id pub-id-type="pmid">10780936</pub-id>
</element-citation></ref><ref id="R16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benson</surname><given-names>RM</given-names></name>
<name><surname>Minter</surname><given-names>LM</given-names></name>
<name><surname>Osborne</surname><given-names>BA</given-names></name>
<name><surname>Granowitz</surname><given-names>EV</given-names></name></person-group><article-title>Hyperbaric oxygen inhibits stimulus-induced proinflammatory cytokine synthesis by human blood-derived monocyte-macrophages</article-title><source>Clin Exp Immunol</source><year>2003</year><volume>134</volume><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">12974755</pub-id>
</element-citation></ref><ref id="R17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weisz</surname><given-names>G</given-names></name>
<name><surname>Lavy</surname><given-names>A</given-names></name>
<name><surname>Adir</surname><given-names>Y</given-names></name>
<etal/></person-group><article-title>Modification of in vivo and in vitro TNF-alpha, IL-1, and IL-6 secretion by circulating monocytes during hyperbaric oxygen treatment in patients with perianal Crohn&#x02019;s disease</article-title><source>J Clin Immunol</source><year>1997</year><volume>17</volume><fpage>154</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">9083891</pub-id>
</element-citation></ref><ref id="R18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thom</surname><given-names>SR</given-names></name></person-group><article-title>Hyperbaric oxygen: its mechanisms and efficacy</article-title><source>Plast Re-constr Surg</source><year>2011</year><volume>127</volume><issue>Suppl 1</issue><fpage>131S</fpage><lpage>141S</lpage></element-citation></ref><ref id="R19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Waili</surname><given-names>NS</given-names></name>
<name><surname>Butler</surname><given-names>GJ</given-names></name></person-group><article-title>Effects of hyperbaric oxygen on inflammatory response to wound and trauma: possible mechanism of action</article-title><source>Scientific World Journal</source><year>2006</year><volume>6</volume><fpage>425</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">16604253</pub-id>
</element-citation></ref><ref id="R20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bekheit</surname><given-names>M</given-names></name>
<name><surname>Baddour</surname><given-names>N</given-names></name>
<name><surname>Katri</surname><given-names>K</given-names></name>
<name><surname>Taher</surname><given-names>Y</given-names></name>
<name><surname>El Tobgy</surname><given-names>K</given-names></name>
<name><surname>Mousa</surname><given-names>E</given-names></name></person-group><article-title>Hyperbaric oxygen therapy stimulates colonic stem cells and induces mucosal healing in patients with refractory ulcerative colitis: a prospective case series</article-title><source>BMJ Open Gastroenterol</source><year>2016</year><volume>3</volume><fpage>e000082</fpage></element-citation></ref><ref id="R21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dulai</surname><given-names>PS</given-names></name>
<name><surname>Gleeson</surname><given-names>MW</given-names></name>
<name><surname>Taylor</surname><given-names>D</given-names></name>
<name><surname>Holubar</surname><given-names>SD</given-names></name>
<name><surname>Buckey</surname><given-names>JC</given-names></name>
<name><surname>Siegel</surname><given-names>CA</given-names></name></person-group><article-title>Systematic review: The safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease</article-title><source>Aliment Pharmacol Ther</source><year>2014</year><volume>39</volume><fpage>1266</fpage><lpage>1275</lpage><pub-id pub-id-type="pmid">24738651</pub-id>
</element-citation></ref><ref id="R22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>X</given-names></name>
<name><surname>Liang</surname><given-names>TY</given-names></name>
<name><surname>Wang</surname><given-names>Z</given-names></name>
<name><surname>Chen</surname><given-names>G</given-names></name></person-group><article-title>The role of hyperbaric oxygen therapy in inflammatory bowel disease: a narrative review</article-title><source>Med Gas Res</source><year>2021</year><volume>11</volume><fpage>66</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">33818446</pub-id>
</element-citation></ref><ref id="R23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rossignol</surname><given-names>DA</given-names></name></person-group><article-title>Hyperbaric oxygen treatment for inflammatory bowel disease: a systematic review and analysis</article-title><source>Med Gas Res</source><year>2012</year><volume>2</volume><fpage>6</fpage><pub-id pub-id-type="pmid">22417628</pub-id>
</element-citation></ref><ref id="R24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wyant</surname><given-names>T</given-names></name>
<name><surname>Fedyk</surname><given-names>E</given-names></name>
<name><surname>Abhyankar</surname><given-names>B</given-names></name></person-group><article-title>An overview of the mechanism of action of the monoclonal antibody vedolizumab</article-title><source>J Crohns Colitis</source><year>2016</year><volume>10</volume><fpage>1437</fpage><lpage>1444</lpage><pub-id pub-id-type="pmid">27252400</pub-id>
</element-citation></ref><ref id="R25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sandborn</surname><given-names>WJ</given-names></name>
<name><surname>Feagan</surname><given-names>BG</given-names></name>
<name><surname>Rutgeerts</surname><given-names>P</given-names></name>
<etal/></person-group><article-title>Vedolizumab as induction and maintenance therapy for Crohn&#x02019;s disease</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><fpage>711</fpage><lpage>721</lpage><pub-id pub-id-type="pmid">23964933</pub-id>
</element-citation></ref><ref id="R26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vermeire</surname><given-names>S</given-names></name>
<name><surname>Loftus</surname><given-names>EV</given-names><suffix>Jr.</suffix></name>
<name><surname>Colombel</surname><given-names>JF</given-names></name>
<etal/></person-group><article-title>Long-term efficacy of vedolizumab for Crohn&#x02019;s disease</article-title><source>J Crohns Colitis</source><year>2017</year><volume>11</volume><fpage>412</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">27683798</pub-id>
</element-citation></ref></ref-list></back></article>